 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Stockwinners Market Radar for February 23, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
| CAT... | Hot Stocks19:37 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Intuit (INTU) is nearing a deal to buy Credit Karma for about $7B in cash and stock, The Wall Street Journal's Cara Lombardo and Dana Cimilluca wrote, citing people familiar with the matter. The maker of TurboTax could announce a deal to buy privately held Credit Karma by Monday, assuming talks don't fall apart, the people said. Credit Karma was valued at roughly $4B in a private share sale about two years ago, the authors noted. 2. Boeing (BA) has confirmed it found debris that could pose potential safety risks in the fuel tanks of several 737 Max aircraft that are in storage and waiting to be delivered to airlines, according to Reuters. Boeing officials called the findings "absolutely unacceptable," the report noted. 3. Intelsat's stock (I) could again become a casualty in a 5G showdown among hedge-fund managers, satellite operators, and the federal government, Alexandra Scaggs wrote in this week's edition of Barron's. The company's satellites transmit television signals over the so-called C-band, which is considered to be prime for fifth-generation, or 5G, service, with regulators wanting to clear out 60% of it for use by wireless companies, the author noted. A consortium of satellite operators called the C-Band Alliance volunteered to sell the spectrum privately in a plan that could have brought Intelsat as much as $24B, but the problem is that a private sale would require the Federal Communications Commission to give satellite operators the ability to sell rights they do not currently have, in the regulator's view, the author added. 4. ViacomCBS (VIAC) subsidiary Paramount's "Sonic the Hedgehog" stayed at number one, grossing another $26.3M in its second weekend in theaters and bringing its total to $106.6M. Overseas, the movie earned $38.3M in 56 markets. "Sonic the Hedgehog" sports an A CinemaScore and a 63% Rotten Tomatoes rating. 5. Caterpillar (CAT) and Kroger (KR) saw positive mentions in this week's edition of Barron's, while Virgin Galactic (SPCE) was mentioned cautiously.
|
| KDMN | Hot Stocks16:05 EST Kadmon announces expanded results of interim analysis of KD025 trial in cGVHD - Kadmon announced expanded results from the previously reported interim analysis of ROCKstar, its ongoing pivotal trial of KD025 in chronic graft-versus-host disease. As announced in November 2019, KD025 met the primary endpoint of Overall Response Rate at the study's planned interim analysis, two months after completion of enrollment. KD025 showed statistically significant and clinically meaningful ORRs of 64% with KD025 200 mg once daily and 67% with KD025 200 mg twice daily. In the expanded KD025-213 dataset presented, ORRs were consistent with the previously reported interim analysis across key subgroups, including in patients with four or more organs affected by cGVHD, patients who had prior treatment with ibrutinib and patients who had prior treatment with ruxolitinib. Three patients achieved a Complete Response. Responses were observed in all affected organ systems, including in organs with fibrotic disease. KD025 has been well tolerated: adverse events were consistent overall with those expected to be observed in cGVHD patients receiving corticosteroids, and no apparent increased risk of infection was observed. Additional secondary endpoints, including duration of response, corticosteroid dose reductions, Failure-Free Survival, Overall Survival and Lee Symptom Scale reductions continue to mature and will be available later in 2020. At the TCT Meetings, Kadmon also presented long-term follow-up data from KD025-208, its ongoing Phase 2 study of KD025 in cGVHD. These data were recently presented at the 61st American Society of Hematology Annual Meeting and Exposition in December 2019.
|
| HOTH SPEX | Hot Stocks16:02 EST Spherix announces special dividend distribution - Spherix (SPEX) announced that on February 21, 2020, a special committee of the Board of Directors of Spherix approved a distribution to Spherix stockholders of 70,000 shares of Hoth Therapeutics (HOTH) held by Spherix. Each Spherix stockholder will be entitled to receive one share of Hoth common stock for every seventy shares of Spherix common stock held as of 5 p.m. Eastern Time on March 4, 2020, the record date. Spherix will not distribute fractional shares of Hoth common stock, and any fractional shares will be rounded down to the nearest whole share.
|
